CBD reduced diabetic nerve pain in rats through serotonin receptors, not cannabinoid receptors | Research

The takeaway

CBD reduced diabetic neuropathic pain in rats through serotonin 5-HT1A receptor activation in the spinal cord, not through CB1 or CB2 cannabinoid receptors, and chronic treatment restored depleted spinal serotonin levels.

People with diabetic neuropathy interested in CBD, anyone using CBD for pain, and researchers studying CBD mechanisms.

CBD worked through serotonin (5-HT1A), not cannabinoid receptors, and restored depleted spinal serotonin

What the researchers found

Acute CBD (0.3 and 3 mg/kg) reduced mechanical allodynia in diabetic rats. The effect was blocked by the 5-HT1A antagonist WAY 100135 but not by CB1 (AM251) or CB2 (AM630) antagonists. Sub-chronic CBD (14 days) produced sustained pain relief and restored depleted spinal cord serotonin levels.

Why it matters

Diabetic neuropathic pain affects most diabetic patients and responds poorly to current treatments. This study shows CBD works through an unexpected mechanism (serotonin, not cannabinoid receptors) and actually corrects the underlying serotonin deficit, not just masking pain.

The numbers in context

CBD 0.3 and 3 mg/kg effective acutely. Effect blocked by 5-HT1A antagonist (WAY 100135 3 mcg/rat intrathecal). Not blocked by CB1 (AM251) or CB2 (AM630) antagonists. 14-day treatment sustained relief. Diabetic rats had lower spinal serotonin; CBD 0.3 mg/kg restored it.

How the study worked

Streptozotocin-induced diabetic rats treated with acute or sub-chronic (14-day) CBD at multiple doses. Mechanical pain threshold assessed with electronic Von Frey. Pharmacological antagonism used to identify the mechanism. Spinal cord serotonin levels measured.

What this study cannot tell us

Rat model of chemically induced diabetes. Intraperitoneal injection, not oral. The serotonergic mechanism found here may not be the only or primary mechanism in other pain types. No human data for CBD in diabetic neuropathy.

How to read the evidence

Preliminary: well-controlled animal study with clear mechanistic findings, but rat model only.

When this study was published

Published in 2019.

The bigger picture

That CBD works through serotonin receptors for neuropathic pain connects it pharmacologically to existing antidepressants used for chronic pain (SSRIs, SNRIs). But CBD may offer pain relief without the side effects of these drugs, if the animal findings translate.

Questions still open

Would oral CBD produce the same serotonergic effects? Could CBD complement existing serotonergic pain medications? Does this mechanism apply to other types of neuropathic pain beyond diabetic?

Common questions

Can CBD help with diabetic nerve pain?

In rats, CBD reduced diabetic neuropathic pain both acutely and with chronic treatment. Surprisingly, it worked through serotonin receptors, not cannabinoid receptors, and actually restored depleted spinal serotonin levels. Human trials are needed.

Why doesn't CBD work through cannabinoid receptors for pain?

CBD has weak affinity for CB1 and CB2 receptors compared to THC. This study confirmed that blocking these receptors didn't affect CBD's pain relief. Instead, CBD activated 5-HT1A serotonin receptors, which are well-established pain modulators.

Read the original research

Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors.

Brain research, 1715, 156-164

View on PubMed ↗Publisher’s paper ↗

Citation

Jesus, Carlos Henrique Alves; Redivo, Daiany Darlly Bello; Gasparin, Aléxia Thamara; Sotomaior, Bruna Bittencourt; de Carvalho, Milene Cristina; Genaro, Karina; Zuardi, Antonio Waldo; Hallak, Jaime Eduardo Cecílio; Crippa, José Alexandre; Zanoveli, Janaina Menezes; da Cunha, Joice Maria. (2019). Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors.. Brain research, 1715, 156-164. https://doi.org/10.1016/j.brainres.2019.03.014